Abstract: A container assembly for encouraging a consumer to make initial and continually purchases of a consumer product by allowing entry into a game of chance with the purchase of the consumer product. The container assembly includes a container for holding a fluid with a first density (D1) at a first pressure (P1) with a breakable seal. A game piece with a given buoyancy, the game piece is placed within the fluid inside the container. When the seal of the container is broken, the first pressure (P1) of the fluid changes to a second pressure (P2), and thereby causing a change in the buoyancy of the game piece to indicate whether the game piece is a winning game piece.

Abstract: At least one exemplary embodiment is directed to an acoustic Dose system comprising: a first device configured to measure sound pressure levels directed to an ear drum; and a second device configured to convert the sound pressure levels into a sound pressure level dose, where the second device sends a notification signal to a third device if the sound pressure level dose is larger than a threshold value.

Abstract: At least one exemplary embodiment is related to a method of device customization comprising: entering physiological data, where the physiological data is obtained from a visual image loaded by a web based software program; selecting device features using the web based software program; and selecting the device appearance using the web based software program.

Abstract: At least one exemplary embodiment is directed to a method of operating an audio device comprising: measuring sound pressure levels (SPLECM) for acoustic energy received by an ear canal microphone (ECM) during a time increment ?t; and calculating a SPL_Dose?t during the time increment ?t using SPLECM.

Abstract: A system for monitoring sound pressure levels at the ear includes an ambient sound microphone (ASM) for receiving ambient sounds and an ear canal microphone (ECM) for producing audio signals as a function of ambient sound received at the ambient sound microphone and sound signal received from an associated personal audio device. A logic circuit is operatively associated with the ASM and ECM calculates a total SPL_Dose experienced by the ear at a time t. In one exemplary embodiment, the total SPL_Dose is calculated by determining SPL_Dose for periods ?t as measured at the ECM. The logic circuit then may then select an action parameter in response to the Total SPL_Dose.

Abstract: A system for monitoring sound pressure levels at the ear includes an ambient sound microphone for receiving ambient sounds and an ear canal microphone for producing audio signals as a function of ambient sound received at the ambient sound microphone and sound signal received from an associated personal audio device. A logic circuit is operatively associated with the ASM and ECR calculates a total SPL_Dose experienced by the ear at a time t. In one exemplary embodiment the total SPL_Dose is calculated by determining estimated SPL_Dose for periods ?t. The logic circuit then may then select an action parameter in response to the Total SPL_Dose.

Abstract: An earpiece is provided that can include an Ambient Sound Microphone (ASM) to measure ambient sound, an Ear Canal Receiver (ECR) to deliver audio to an ear canal, an Ear Canal Microphone (ECM) to measure a sound pressure level within the ear canal, and a processor to produce the audio from at least in part the ambient sound, actively monitor a sound exposure level inside the ear canal, and adjust a level of the audio to within a safe and subjectively optimized listening level range based on the sound exposure level. An audio interface can deliver audio content from a media player. The processor can selectively mix the audio content with the ambient sound to produce the audio in accordance with a personalized hearing level (PHL) to permit environmental awareness of at least one distinct sound in the ambient sound. Other embodiments are disclosed.

Abstract: At least one exemplary embodiment is directed to a method of monitoring sound pressure level comprising: measuring a first sound pressure level in the ear canal; measuring a second sound pressure level out of the ear canal; calculating a first sound pressure level dose using the first sound pressure level, where if the first sound pressure level is below a permissible sound level a recovery function is used to calculate the first sound pressure level dose; and calculating a second sound pressure level dose using the second sound pressure level.

Abstract: The invetion relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the description, their use as medicament, pharmaceutical compositions containing them and processes for their preparation.

Abstract: The invention relates to compounds of formula (I) 1

Abstract: Novel indolyl-2-phenyl bisamidines are described which are DNA methyltransferase inhibiting agents, and pharmaceutical compositions containing them are used as antiproliferative agents for treating a disease, especially a neoplastic disease, characterized by abnormally rapid proliferation of tissue involved in said disease; said indolyl-2-phenyl bisamidines comprising a and a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen or (C1-C3)alkyl; R3, R4, R5, R8, R9, and R10 are hydrogen or (C1-C3)alkyl, or R3 and R4 may be taken together, or R8 and R9 may be taken together with the nitrogen atoms to which they are attached, to form an imidazolinyl group; R14 is —H; —NHC(═O)(CH2)mR20; —(CH2)mR20; —CH(CH3)R20; —(CH2)m(C6H3)—R17; —(CH2)m(C6H3)—R20; —(CH2)m(heterocyclyl)—R17; —(CH2)m(heterocyclyl)—R20; —CH2CH═CHR20; —(CH2)mC(═O)NH—CHR20R21; or —(CH2)mC(═O)NH—CH2&m

Abstract: The present invention relates to compounds of formula I and to pharmaceutically acceptable salts, hydrates and prodrugs thereof, wherein R1, R2, R3, R4, R5, R10, R11, b, m, n, p and v are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and methods of treating hyperproliferative disorders in mammals by administering the above compounds.

Abstract: A method of treating hyperproliferation diseases in mammals in need of such treatment, which method includes administering to said mammal a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein R1, R2, R3, R4, W, X, Y, Z and t are as defined herein.

Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Abstract: Known bisamidine compounds are newly discovered to possess DNA methyltransferase inhibiting properties, making them useful for preparing pharmaceutical compositions useful as antiproliferative agents for treating a neoplastic or a non-neoplastic disease characterized by abnormally rapid proliferation of tissue involved in said disease; wherein said bisamidines comprise a compound of Formula (5.0.0): and a pharmaceutically acceptable salt thereof, wherein: —X is —C(R34)—; or —N—; —R23, R24, R28 and R29 are each independently —H; or —CH2— where R23 and R24 and R28 and R29 are taken together with the nitrogen atoms to which they are attached, to form an imidazolinyl group; and —R34 is —H; or —CH3. A preferred species of Formula (5.0.0) is the following: 2-(4-Carbamimidoyl-phenyl)-1H-indole-6-carboxamidine.

Abstract: A method of treating hyperproliferation diseases in mammals in need of such treatment which method includes administering to said mammal a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein R1, R2, R3, R4, W, X, Y, Z and t are as defined herein.

Abstract: This invention relates to novel aryl substituted azabenzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof wherein n is an integer from 1 to 4 X is CH or N; R1 is H, (C1-C6)alkyl or (C1-C6) alkoxy; R2 is H, (C1-C6)alkyl or (C1-C6) alkoxy; each R3 is independently selected from H, (C1-C6)alkyl (C1-C6) alkyloxy, (C1-C6) alkylthio, halo, nitro, cyano, ethynyl, hydroxy and trifluoromethyl; R4 is H, (C1-C6)alkyl or (C1-C6) alkoxy; R5 is H, (C1-C6)alkyl or (C1-C6) alkyloxy, trifluoromethyl; and W is N or C; Y is N (R4), N, S or O Z is R4, NR4H, O, or OH; Provided that when Y═NR4, W═C, Z═O, there is a single bond between YW and a double bond between WZ; and when Y=O or S, W═C, Z═O, there is a single bond between YW and a double bond between WZ; and when Y═N, W═N, there is a double bond between YW and Z does not exist.

Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Abstract: An (N-(pyridinylmethyl)-heterocyclic)ylideneamine compound of the formula ##STR1## wherein R.sup.3, A, and B are as described below, and its pharmaceutically acceptable salts and prodrugs. Compounds of the formula I and their pharmaceutically acceptable salts and prodrugs are useful in the treatment of addictive disorders, such as the use of tobacco or other nicotine containing products, neurological and mental disorders such as senile dementia of the Alzheimer's type, Parkinson's disease, attentional hyperactivity disorder, anxiety, obesity, Tourette's Syndrome and ulcerative colitis.

Abstract: Indole carboxylic acids are useful as UGGTASE inhibitors.